Last edition
News about "tau-targeted therapy"
Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease
Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).
Tau-targeted Therapy | 15/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members